Kanabe S, Tamakuma S, Mimura K, Hiraide H, Mochizuki H, Tamaki K, Kurokawa T, Kadota T, Hatsuse K, Kawano M
Gan No Rinsho. 1985 Nov;31(14):1805-9.
Fifty-eight patients with stage IV gastric carcinoma were studied for the 24-month survival rate after receiving immunochemotherapy (Mitomycin-C + FT 207 + OK 432 + PSK, 29 cases) and chemotherapy Mitomycin-C + FT 207, 29 cases). There were no differences in the background factors influencing survival time between the two groups. The survival rate of the immunochemotherapy group was higher than, that of chemotherapy group throughout the observation period, in addition to statistical significance in some periods. The 50% survival rate was 10 months, in the chemotherapy group and 18 months in immunochemotherapy group. The difference in survival between the nonresected cases with immunochemotherapy and the resected cases with chemotherapy was smaller than that between nonresected cases and resected cases of the chemotherapy or immunochemotherapy group. These results suggested that possibility that immunochemotherapy prolonged the survival of patients with stage IV gastric carcinoma.
对58例IV期胃癌患者进行了研究，观察其接受免疫化疗（丝裂霉素-C+替加氟+溶链菌制剂+云芝多糖，29例）和化疗（丝裂霉素-C+替加氟，29例）后的24个月生存率。两组之间影响生存时间的背景因素没有差异。在整个观察期内，免疫化疗组的生存率高于化疗组，在某些时期还具有统计学意义。化疗组的50%生存率为10个月，免疫化疗组为18个月。免疫化疗的未切除病例与化疗的切除病例之间的生存差异小于化疗或免疫化疗组的未切除病例与切除病例之间的差异。这些结果提示免疫化疗有可能延长IV期胃癌患者的生存期。
